CNBC
Weight loss drug maker sinks 25% after new safety data spooks investors
EconomyDaily Composite
While the experimental drug met its key targets, analysts are concerned over the commercial opportunity due to side effects.
C
Source
CNBC
Read full article at CNBC
Opens original article in a new tab
Advertisement